Patent · US Active

Compositions and methods for immunotherapy

US10654928B2 · kind B2 · utility

9Cited by
1References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 1, 2015
Grant dateMay 19, 2020
Priority date
Expiry dateApr 1, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2999/002
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.